Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
10
2023 to 2026
Breakthrough
1
Accelerated
0
Priority review
2
Orphan
3
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2023 | 5 | 0 |
| 2024 | 1 | 0 |
| 2025 | 2 | 0 |
| 2026 | 1 | 1 |
10 approvals
Newest first. Hover a badge for what it means.
- Lytenava (Bevacizumab-Vikg) · Outlook Therapeutics, Inc.Jul 24, 2026
To treat patients with neovascular (wet) age-related macular degeneration
- Differin Epiduo Acne Gel (Adapalene and Benzoyl Peroxide) (Adapalene, Benzoyl Peroxide, Adapalene, Benzoyl Peroxide) · Galderma Labs LpMay 22, 2026Original approval · NDA 220736Approval letter
- Vizz (Aceclidine Hydrochloride) · Lenz TherapJul 31, 2025
To treat presbyopia
- Tryptyr (Acoltremon) · Alcon Labs INCMay 28, 2025
To treat the signs and symptoms of dry eye disease
- Attruby (Acoramidis Hydrochloride) · Bridgebio PharmaNov 22, 2024
To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis
- Wainua (Autoinjector) (Eplontersen Sodium) · Astrazeneca AbDec 21, 2023
To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
- Cabtreo (Adapalene, Benzoyl Peroxide, Clindamycin Phosphate) · BauschOct 20, 2023Original approval · NDA 216632Approval letter
- Sohonos (Palovarotene) · IpsenAug 16, 2023
To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva
- Izervay (Avacincaptad Pegol Sodium) · AstellasAug 4, 2023
To treat geographic atrophy secondary to age-related macular degeneration
- Miebo (Perfluorohexyloctane) · Bausch and Lomb INCMay 18, 2023
To treat signs and symptoms of dry eye disease
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.